Abstract
Pregnant women at risk of preterm labor routinely receive glucocorticoids (GCs) and frequently also progesterone. Administration of GCs accelerates intrauterine surfactant synthesis and lung maturation, thereby reducing the incidence of neonatal respiratory distress syndrome; progesterone has the potential to prevent preterm birth. Little is known about possible interactions of GCs and progesterone. Our aim was to clarify whether progesterone can affect dexamethasone (DXM)-regulated expression of surfactant protein A (SP-A), SP-B, and SP-D in lung epithelial cells. H441 cells were exposed to DXM and progesterone and expression of SPs was analyzed by quantitative real-time polymerase chain reaction and immunoblotting. Although progesterone had no direct effect on the expression of SP-B, DXM-mediated induction was inhibited dose dependently on the transcriptional (64 μM [P <.0001], 32 μM [P -.0005], 16 μM [P -.0019]) and the translational level. Furthermore, progesterone inhibited stimulatory effects of other GCs as well. While exogenous tissue growth factor β1 (TGF-β1) inhibited DXM-induced SPB expression (messenger RNA [mRNA]: P -.0014), progesterone itself did not influence TGF-β1 mRNA expression and/or TGFβ1/ Smad signaling, demonstrating that TGF-β1 and/or Smad activation is not involved. The inhibitory effect of progesterone could be imitated by the GC and progesterone receptor (PR) antagonist RU-486, but not by the specific PR antagonist PF-02413873, indicating that progesterone acts as a competitive antagonist of DXM. The effect of progesterone on DXM-regulated genes was not specific for SP-B, as expression of SP-A and SP-D mRNAs was also antagonized. The present study highlights a new action of progesterone as a potential physiological inhibitor of GC-dependent SP expression in lung epithelial cells. The clinical relevance of this in vitro finding is currently unknown.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Eichenwald EC, Stark AR. Management and outcomes of very low birth weight. N Engl J Med. 2008;358(16):1700–1711.
Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science. 2014;345(6198):760–765.
Iams JD. Clinical practice. Prevention of preterm parturition. N Engl J Med. 2014;370(3):254–261.
Hallman M. The story of antenatal steroid therapy before preterm birth. Neonatology. 2015;107(4):352–357.
Malloy MH. Antenatal steroid use and neonatal outcome: United States 2007. J Perinatol. 2012;32(9):722–727.
Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2017;21(3).
Goodnight W. Clinical application of progesterone for the prevention of preterm birth, 2016. Am J Perinatol. 2016;33(3):253–257.
Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol. 2012;206(2):11.
Trotter A, Maier L, Grill HJ, Kohn T, Heckmann M, Pohlandt F. Effects of postnatal estradiol and progesterone replacement in extremely preterm infants. J Clin Endocrinol Metab. 1999; 84(12):4531–4535.
Trotter A, Maier L, Kron M, Pohlandt F. Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed. 2007;92(2):F94–F98.
Perez-Gil J, Weaver TE. Pulmonary surfactant pathophysiology: current models and open questions. Physiology. 2010;25(3):132–141.
Rausch F, Schicht M, Brauer L, Paulsen F, Brandt W. Protein modeling and molecular dynamics simulation of the two novel surfactant proteins SP-G and SP-H. J Mol Model. 2014;20(11):2513.
Bersani I, Speer CP, Kunzmann S. Surfactant proteins A and D in pulmonary diseases of preterm infants. Expert Rev Anti Infect Ther. 2012;10(5):573–584.
Weaver TE, Conkright JJ. Function of surfactant proteins B and C. Annu Rev Physiol. 2001;63:555–578.
Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med. 2002;347(26):2141–2148.
Speer CP, Robertson B, Curstedt T, et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics. 1992;89(1):13–20.
Fehrholz M, Hutten M, Kramer BW, Speer CP, Kunzmann S. Amplification of steroid-mediated SP-B expression by physiological levels of caffeine. Am J Physiol Lung Cell Mol Physiol. 2014;306(1):25.
Beers MF, Solarin KO, Guttentag SH, et al. TGF-beta1 inhibits surfactant component expression and epithelial cell maturation in cultured human fetal lung. Am J Physiol. 1998;275(5 pt 1):L950–L960.
Kumar AS, Gonzales LW, Ballard PL. Transforming growth factor- beta(1) regulation of surfactant protein B gene expression is mediated by protein kinase-dependent intracellular translocation of thyroid transcription factor-1 and hepatocyte nuclear factor 3. Biochim Biophys Acta. 2000;1492(1):45–55.
Kunzmann S, Wright JR, Steinhilber W, et al. TGF-beta1 in SP-A preparations influence immune suppressive properties of SP-A on human CD4+ T lymphocytes. Am J Physiol Lung Cell Mol Physiol. 2006;291(4):28.
Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. 1996;7(4):469–480.
Dammeier J, Beer HD, Brauchle M, Werner S. Dexamethasone is a novel potent inducer of connective tissue growth factor expression. Implications for glucocorticoid therapy. J Biol Chem. 1998;273(29):18185–18190.
Fehrholz M, Glaser K, Speer CP, Seidenspinner S, Ottensmeier B, Kunzmann S. Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts. Respir Res. 2017;18(1):51.
Bungay PJ, Tweedy S, Howe DC, Gibson KR, Jones HM, Mount NM. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist. Drug Metab Dispos. 2011;39(8):1396–1405.
Brower M, Carney DN, Oie HK, Gazdar AF, Minna JD. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 1986;46(2):798–806.
Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF betainducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J. 1998;17(11):3091–3100.
Fehrholz M, Bersani I, Kramer BW, Speer CP, Kunzmann S. Synergistic effect of caffeine and glucocorticoids on expression of surfactant protein B (SP-B) mRNA. PLoS One. 2012;7(12):e51575.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
Joensuu H, Kero P, Pulkkinen MO. Lung tissue progesterone in the human fetus and neonate. Biol Neonate. 1981;40(3-4):183–186.
Pulkkinen MO, Kero P. Effect of progesterone on the initiation of respiration of the newborn. Biol Neonate. 1977;32(3-4):218–221.
Kero PO, Pulkkinen MO. Plasma progesterone in the respiratory distress syndrome. Eur J Pediatr. 1979;132(1):7–10.
Hercz P, Varady E, Ungar L, Siklos P, Buky B. Respiratory distress syndrome: steroid and peptide hormone levels in maternal venous blood and the umbilical vein and artery. Acta Paediatr Hung. 1987;28(1):17–21.
Schmidt M, Renner C, Loffler G. Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998;158(3):401–407.
von Langen J, Fritzemeier KH, Diekmann S, Hillisch A. Molecular basis of the interaction specificity between the human glucocorticoid receptor and its endogenous steroid ligand cortisol. Chembiochem. 2005;6(6):1110–1118.
Pearce D, Yamamoto KR. Mineralocorticoid and glucocorticoid receptor activities distinguished by nonreceptor factors at a composite response element. Science. 1993;259(5098):1161–1165.
Schmidt C, Klammt J, Thome UH, Laube M. The interaction of glucocorticoids and progesterone distinctively affects epithelial sodium transport. Lung. 2014;192(6):935–946.
Deterding RR, Shimizu H, Fisher JH, Shannon JM. Regulation of surfactant protein D expression by glucocorticoids in vitro and in vivo. Am J Respir Cell Mol Biol. 1994;10(1):30–37.
O’Reilly MA, Gazdar AF, Morris RE, Whitsett JA. Differential effects of glucocorticoid on expression of surfactant proteins in a human lung adenocarcinoma cell line. Biochim Biophys Acta. 1988;970(2):194–204.
Liggins GC. Premature parturition after infusion of corticotrophin or cortisol into foetal lambs. J Endocrinol. 1968;42(2):323–329.
Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. J Endocrinol. 1969;45(4):515–523.
Ogueh O, Jones J, Mitchell H, Alaghband-Zadeh J, Johnson MR. Effect of antenatal dexamethasone therapy on maternal plasma human chorionic gonadotrophin, oestradiol and progesterone. Human Reproduct. 1999;14(2):303–306.
Trotter A, Kipp M, Schrader RM, Beyer C. Combined application of 17beta-estradiol and progesterone enhance vascular endothelial growth factor and surfactant protein expression in cultured embryonic lung cells of mice. Int J Pediatr. 2009;2009:170491.
Bosse R, Rivest R, Di Paolo T. Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res. 1997;46(1-2):343–346.
Watson CS, Alyea RA, Hawkins BE, Thomas ML, Cunningham KA, Jakubas AA. Estradiol effects on the dopamine transporter- protein levels, subcellular location, and function. J Mol Signal. 2006;1:5.
Ishii H, Tsurugizawa T, Ogiue-Ikeda M, et al. Local production of sex hormones and their modulation of hippocampal synaptic plasticity. Neuroscientist. 2007;13(4):323–334.
Shields AD, Wright J, Paonessa DJ, et al. Progesterone modulation of inflammatory cytokine production in a fetoplacental artery explant model. Am J Obstet Gynecol. 2005;193(3 pt 2):1144–1148.
Vandenberg LN, Colborn T, Hayes TB, et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev. 2012;33(3):378–455.
Watson CS, Hu G, Paulucci-Holthauzen AA. Rapid actions of xenoestrogens disrupt normal estrogenic signaling. Steroids. 2014;81:36–42.
Kirk CJ, Bottomley L, Minican N, et al. Environmental endocrine disrupters dysregulate estrogen metabolism and Ca2+ homeostasis in fish and mammals via receptor-independent mechanisms. Comp Biochem Physiol A Mol Integr Physiol. 2003;135(1):1–8.
Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res. 1989;49(13):3474–3481.
Acknowledgments
The authors are grateful to Dr S. Itoh (Research Laboratories, Kyowa Hakko Kogyo, Tokyo, Japan) for providing the pGL3ti (CAGA)12 and p3TP-vector and Pfizer Worldwide Research & Development for providing PF-02413873.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Kunzmann, S., Ottensmeier, B., Speer, C.P. et al. Progesterone Antagonizes Dexamethasone-Regulated Surfactant Proteins In Vitro. Reproductive Sciences 26, 1062–1070 (2019). https://doi.org/10.1177/1933719118804668
Published:
Issue Date:
DOI: https://doi.org/10.1177/1933719118804668